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Abstract
Adult height and sitting height may reflect genetic and environmental factors, including early
life nutrition, physical and social environments. Previous studies have reported divergent
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associations for height and chronic disease mortality, with positive associations observed
for cancer mortality but inverse associations for circulatory disease mortality. Sitting height
might be more strongly associated with insulin resistance; however, data on sitting height
and mortality is sparse. Using the European Prospective Investigation into Cancer and
Nutrition study, a prospective cohort of 409,748 individuals, we examined adult height and
sitting height in relation to all-cause and cause-specific mortality. Height was measured in
the majority of participants; sitting height was measured in ~253,000 participants. During an
average of 12.5 years of follow-up, 29,810 deaths (11,931 from cancer and 7,346 from circula-
tory disease) were identified. Hazard ratios (HR) with 95% confidence intervals (CI) for death
were calculated using multivariable Cox regression within quintiles of height. Height was posi-
tively associated with cancer mortality (men: HRQ5 vs. Q1 = 1.11, 95%CI = 1.00–1.24; women:
HRQ5 vs. Q1 = 1.17, 95%CI = 1.07–1.28). In contrast, height was inversely associated with cir-
culatory disease mortality (men: HRQ5 vs. Q1 = 0.63, 95%CI = 0.56–0.71; women: HRQ5 vs. Q1 =
0.81, 95%CI = 0.70–0.93). Although sitting height was not associated with cancer mortality, it
was inversely associated with circulatory disease (men: HRQ5 vs. Q1 = 0.64, 95%CI = 0.55–
0.75; women: HRQ5 vs. Q1 = 0.60, 95%CI = 0.49–0.74) and respiratory disease mortality (men:
HRQ5 vs. Q1 = 0.45, 95%CI = 0.28–0.71; women: HRQ5 vs. Q1 = 0.60, 95%CI = 0.40–0.89). We
observed opposing effects of height on cancer and circulatory disease mortality. Sitting height
was inversely associated with circulatory disease and respiratory disease mortality.
Introduction
Poor nutrition, illness and early life exposures may contribute to ill health in later life [1–3];
however, there is a paucity of data to explore such associations in prospective cohorts with
extended follow-up of children. Adult height is an easily measured variable, and is thought to
reflect both genetic and environmental factors including nutrition, physical and social envi-
ronments in early life [4, 5].
The association between height and mortality has been investigated in previous studies.
A meta-analysis of 121 cohort studies comprising over 1 million participants reported that
height was inversely associated with risk of death from circulatory diseases such as coronary
disease, stroke and heart failure [6]. In contrast, height was positively associated with risk of
death from melanoma and cancers of the pancreas, endocrine and nervous systems, ovary,
breast, prostate, colorectum, blood and lung [6]. Despite many studies investigating overall
height and mortality, there have been few studies examining the association between sitting
height and mortality. Higher sitting height is of interest because compared with adult
height, sitting height may be more strongly positively associated with insulin resistance [7],
and is positively associated with lung function, independently of height [8]; therefore, the
effects of sitting height on mortality might be different from those of overall height. One
cohort study reported that sitting height was positively associated with cancer mortality and
inversely associated with death from circulatory disease [9], but others showed no associa-
tion [7, 10–12].
To further knowledge on the association of height and health outcomes among adults, we
examined whether adult height and sitting height were associated with overall and cause-spe-
cific mortality in a large prospective cohort of approximately half a million men and women
from 10 European countries.
Height, sitting height and mortality
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Methods
Study cohort
The European Prospective Investigation into Cancer and Nutrition (EPIC) study includes 23
centres within 10 European countries (Denmark, France, Germany, Greece, Italy, the Nether-
lands, Norway, Spain, Sweden, and the United Kingdom (UK)). Most centres recruited from
the general population living in defined towns and provinces. In Florence (Italy) and Utrecht
(the Netherlands), however, participants undergoing breast cancer screening were recruited;
parts of the Italian and Spanish cohorts were recruited among blood donors and their spouses;
most of the Oxford cohort (UK) consisted of vegetarian and health-conscious volunteers; and
female members of the health insurance scheme for state school employees were recruited in
France. Between 1992 and 2000, 521,457 individuals (approximately 70% women, mostly 20–
70 years old) were enrolled after providing written informed consent. Ethical approval for the
EPIC study was obtained from the review boards of the International Agency for Research on
Cancer (IARC) and local participating centres. The cohort characteristics have been described
in detail elsewhere [13, 14].
Exposure assessment
At recruitment, standardized questionnaires on lifestyle, demographic information and per-
sonal history were collected [13, 14]. Height was measured in participating centres to the nearest
0.1, 0.5, or 1.0 cm in participants without shoes on [15]. Norway was the only centre in which
height was all self-reported; furthermore, height was only measured in 29% of the French and
13% of the Oxford cohort with the remainder of the participants self-reporting their height.
Self-reported data on height tends to be overestimated, with the degree of overestimation being
larger for shorter individuals and this also depends on age [15]. The self-reported data from the
Oxford cohort were adjusted using earlier described sex-specific regression equations that
incorporated age [15]; this was not done for the French cohort because the interval between the
self-reported data and measurement was considered to be too long to do so reliably, thus only
those participants with measured data were included. Sitting height was measured (the mini-
mum unit was 0.1cm) in over 90% of participants in six countries (Italy, Spain, the Netherlands,
Germany, Greece, Denmark) and in 29% of French participants.
Follow-up and endpoint assessment
Vital status, causes and dates of death were ascertained from population registries in Denmark,
Italy (except Naples), the Netherlands, Norway, Spain, Sweden, and the UK. In Germany,
Greece and Naples, this information was obtained by follow-up mailings or inquiries to
municipal registries, regional health departments, physicians, and hospitals, and also by
directly contacting their next-of-kin. In France, the causes and dates of death were obtained
from the French Epidemiological Center for the Medical Causes of Death (Ce´piDc, Inserm).
Mortality data were coded according to the 10th revision of the International Classification
of Diseases (ICD-10). All-cause mortality included deaths from external causes. The codes for
the underlying cause of death were classified as follows: circulatory (ICD-10: I00-I99), cancer
(C00-C97), respiratory (J00-J99), other or not reported (all other codes). Additionally, cancers
were classified as smoking-related cancers [16] (oral cavity (C00-06), pharynx (C10), naso-
pharynx (C11-13), oesophagus (C15), stomach (C16), colorectal (C18-20), liver (C22), bile
duct (C24), pancreas (C25), larynx and lung (C32-34), uterine cervix (C53), ovarian (C56),
kidney and renal pelvis, ureter and bladder (C64-68), and myeloid leukaemia (C92) [16])
and non-smoking-related cancers (all other cancers). Furthermore, circulatory disease was
Height, sitting height and mortality
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subdivided into ischaemic heart disease (I20-I25), myocardial infarction (I21), cerebrovascular
disease (I60-I69), haemorrhagic stroke (I60-I62) and ischemic stroke (I63).
Statistical analysis
From the 521,457 participants recruited, those in a subsample in France (n = 52,809) and in
the whole cohort in Norway (n = 37,185) were excluded because measured height was unavail-
able. Additionally, participants with missing questionnaire data (n = 1,286), missing dietary
data (n = 6,627), missing all potential confounders (n = 3,127), without dates of death or fol-
low-up information (n = 542) and those within the lowest and highest 1% of the cohort distri-
bution of the ratio of reported total energy intake to energy requirements (n = 10,133) were
excluded [17]. The final analytic cohort consisted of 409,748 individuals. For the analysis of sit-
ting height, participants whose sitting height was not assessed were also excluded, leaving an
analytic cohort for sitting height of 253,427 individuals.
Cox proportional hazard regression models with age as the underlying time scale were used
to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between
height, sitting height and mortality risk. Height and sitting height were analysed as categorical
variables defined by quintiles, and rounded off to the nearest 1 cm, and as continuous vari-
ables. Time at risk was estimated from the date of recruitment to the date of death, emigration,
loss to follow-up, or the end of follow-up (a maximum through 2010, depending on centre),
whichever occurred first. To control for differences in questionnaire design and follow-up pro-
cedures, all models were stratified by study centre. Models were further stratified by age at
recruitment (continuous) to allow the form of the baseline hazard functions to vary across ages.
All models were fitted for men and women separately, and adjusted for weight (kg, quintiles),
combined recreational and household physical activity (inactive, moderately inactive, moder-
ately active, active, unknown), alcohol consumption (0,>0–4, 5–14, 15–29, 30–59, 60 g/day),
smoking status (never, former smokers (who quit<10 or10 years ago), current smokers (1–
14, 15–24 or25 cigarettes per day), current smoker but amount missing (unknown smoking
status), education level (none/primary school, technical or professional school, secondary
school, university degree, not specified/missing) and energy intake (kcals/day, continuous).
Moreover, the Cox models for women were further adjusted for menopausal status (pre, post-,
peri-menopausal or unknown) and menopausal hormone use (yes, no, unknown). Potential
non-linearity of the dose-response relationship was investigated using restricted cubic spline
regression with knots placed at the 5th, 25th, 75th and 95th percentiles of height and correspond-
ing likelihood ratio tests to compare the goodness-of-fit of the models with and without the
spline terms [18, 19]. Because linearity could indeed be assumed, we computed a test for trend
based on models with height and sitting height as a continuous variable.
Finally, we conducted interaction analyses to examine the relation between sitting height
and overall height in relation to mortality; for these analyses we categorized height and sitting
height into tertiles (low, middle and high) and examined risks within each combined strata
and calculated a P-value for the interaction term. In addition, we examined interaction terms
for height (as a continuous variable, per 5cm increment) and all-cause and cause-specific mor-
tality according to country, age at recruitment, body mass index (BMI), smoking status and
alcohol intake.
All reported P-values were two-sided and were regarded as statistically significant if
P<0.05. The potential for multiple comparisons was addressed by examining Bonferroni cor-
rection; p = 0.004 (0.05/13 variables). All analyses were performed using Statistical Analysis
Software (SAS version 9.1, SAS Institute, Cary, NC).
Height, sitting height and mortality
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Results
After an average follow-up of 12.5 years (range 0.01–17.8), 29,810 participants (15,320 men
and 14,490 women) had died from any cause among all 409,748 participants. Out of all deaths
with a reported cause (n = 25,526), major causes were cancer (n = 11,931), diseases of the cir-
culatory system (n = 7,346) and the respiratory tract (n = 1,266). Among participants with data
on sitting height, there were 15,630 all-cause deaths, 6,909 deaths from cancer, and 3,656
deaths from circulatory diseases. Participants who were taller, compared with those who were
shorter, were younger, heavier, had higher energy intakes and were more physically active.
The proportion of current smokers was lower in taller men but there was a higher proportion
of current smokers in taller women; furthermore, taller women were more likely to have a
higher education level, consume higher levels of alcohol, to be premenopausal, and among
post-menopausal women, were more likely to use menopausal hormones (Table 1). After
excluding individuals without data for sitting height, the characteristics were similar to those
with measured height (data not shown).
Tables 2 and 3 shows the HRs for height and all-cause and cause-specific mortality in
men and women, respectively. There was a statistically significant linear inverse association
between height and all-cause mortality in men (HRQ5 vs. Q1 = 0.85, 95%CI = 0.80–0.91, p for
trend<0.01), but no association was observed in women (HRQ5 vs. Q1 = 1.01, 95%CI = 0.95–
1.08, p for trend = 0.66). We observed a positive association between height and death from
cancer in both sexes (HRQ5 vs. Q1 = 1.11, 95%CI = 1.00–1.24, p for trend = 0.08 in men;
HRQ5 vs. Q1 = 1.17, 95%CI = 1.07–1.28, p for trend<0.01 in women). HRs for smoking-re-
lated cancers and non-smoking-related cancers were not substantially different (Table 3).
In contrast, height was inversely associated with the risk of death from circulatory disease in
both sexes (HRQ5 vs. Q1 = 0.63, 95%CI = 0.56–0.71, p for trend<0.01 in men; HRQ5 vs. Q1 =
0.81, 95%CI = 0.70–0.93, p for trend<0.01 in women). Furthermore, height was inversely
associated with ischaemic heart disease and myocardial infarction in both men and women,
as well as cerebrovascular disease mortality in men only. There was no association between
height and death from stroke or respiratory diseases in men or women. Excluding subjects
with a past history of cancer, cardiovascular disease or diabetes (n = 38,760) yielded similar
results (data not shown).
Tables 4 and 5 shows the HRs for sitting height and all-cause and cause-specific mortality
in men and women, respectively. We observed inverse associations for sitting height and all-
cause mortality in both men and women (HRQ5 vs. Q1 = 0.81, 95%CI = 0.74–0.88, p for
trend<0.01 in men; HRQ5 vs. Q1 = 0.86, 95%CI = 0.79–0.94, p for trend<0.01 in women). In
contrast to the findings for overall height, we did not observe an association between sitting
height and cancer mortality in either men or women. The associations between sitting height
and circulatory disease mortality were similar to the inverse findings for overall height. In
addition, we observed an inverse association between sitting height and death from haemor-
rhagic stroke in men only (HRQ5 vs. Q1 = 0.44, 95%CI = 0.23–0.84, p for trend<0.01) and from
respiratory disease in men and women (HRQ5 vs. Q1 = 0.45, 95%CI = 0.28–0.71, p for trend
<0.01; HRQ5 vs. Q1 = 0.60, 95%CI = 0.40–0.89, p for trend<0.01, respectively). When we ana-
lysed the association between sitting height and mortality, additional adjustment for overall
height did not substantially change our results.
We also investigated interactions between sitting height and overall height in relation to
mortality (Table 6). Taller overall height and taller sitting height was strongly inversely associ-
ated with death from respiratory disease in men (Pinteraction = 0.03) but not women. However,
there were no significant interactions between sitting height and overall height in relation to
all-cause, cancer or circulatory disease mortality. Interaction terms for overall height and
Height, sitting height and mortality
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mortality by age, smoking status (smoker/non-smoker), and alcohol intake (high/low) did not
reveal meaningful differences; however, for BMI, we observed an increased risk per 5cm incre-
ment in height for all-cause mortality only among women with a BMI<25 kg/m2 (data not
shown).
After Bonferroni correction, the significance of our results was not substantially changed.
Discussion
In this large prospective study, overall height was positively associated with deaths from can-
cer, but inversely associated with deaths from circulatory disease. These results are supported
Table 6. Hazard ratios* and 95% confidence intervals for all-cause and cause-specific mortality according to sitting height and overall height in
men and women.
Overall height (tertiles)
Lowest (<170 cm) Middle (170-<176 cm) Highest (≧92 cm) Pinteraction
MEN
All-cause mortality Lowest (<89 cm) 1 0.89 (0.82–0.97) 1.04 (0.87–1.24)
Middle (89-<92 cm) 0.99 (0.90–1.08) 0.88 (0.82–0.96) 0.81 (0.73–0.90) 0.58
Highest (≧92 cm) 0.99 (0.79–1.25) 0.91 (0.83–1.00) 0.83 (0.76–0.90)
All cancer Lowest (<89 cm) 1 0.93 (0.81–1.07) 1.18 (0.89–1.56)
Middle (89-<92 cm) 1.08 (0.93–1.26) 1.03 (0.91–1.16) 0.98 (0.83–1.15) 0.77
Highest (≧92 cm) 1.03 (0.71–1.48) 1.18 (1.02–1.36) 1.08 (0.95–1.23)
Circulatory disease Lowest (<89 cm) 1 0.75 (0.64–0.89) 0.74 (0.50–1.08)
Middle (89-<92 cm) 0.95 (0.80–1.12) 0.75 (0.65–0.87) 0.58 (0.47–0.72) 0.53
Highest (≧92 cm) 0.91 (0.60–1.39) 0.70 (0.58–0.84) 0.62 (0.53–0.73)
Respiratory disease Lowest (<89 cm) 1 1.27 (0.87–1.84) 1.22 (0.48–3.09)
Middle (89-<92 cm) 0.79 (0.49–1.28) 0.69 (0.45–1.04) 0.36 (0.17–0.75) 0.03
Highest (≧92 cm) 0.71 (0.17–2.92) 0.84 (0.51–1.38) 0.50 (0.32–0.80)
Sitting height (tertiles) Lowest (<158cm) Middle (158-<163 cm) Highest (≧163 cm) Pinteraction
WOMEN
All-cause mortality Lowest (<84 cm) 1 1.07 (0.98–1.16) 1.15 (0.95–1.39)
Middle (84-<87 cm) 0.91 (0.82–1.00) 1.00 (0.93–1.08) 1.02 (0.93–1.12) 0.29
Highest (≧87 cm) 1.04 (0.83–1.30) 0.91 (0.82–1.01) 0.93 (0.86–1.01)
All cancer Lowest (<84 cm) 1 1.07 (0.94–1.23) 1.19 (0.91–1.55)
Middle (84-<87 cm) 1.04 (0.89–1.20) 1.14 (1.02–1.27) 1.08 (0.94–1.25) 0.66
Highest (≧87 cm) 1.24 (0.91–1.68) 0.99 (0.85–1.15) 1.09 (0.97–1.23)
Circulatory disease Lowest (<84 cm) 1 1.19 (0.99–1.44) 1.30 (0.85–1.98)
Middle (84-<87 cm) 0.84 (0.67–1.06) 0.89 (0.74–1.07) 0.88 (0.70–1.12) 0.05
Highest (≧87 cm) 0.97 (0.59–1.60) 0.86 (0.67–1.09) 0.75 (0.62–0.91)
Respiratory disease Lowest (<84 cm) 1 0.67 (0.43–1.10) 1.43 (0.64–3.16)
Middle (84-<87 cm) 0.46 (0.25–0.84) 0.85 (0.59–1.22) 1.07 (0.70–1.62) 0.11
Highest (≧87 cm) 0.31 (0.04–2.25) 0.72 (0.43–1.19) 0.71 (0.48–1.05)
* Hazard ratios (HR) and 95% confidence intervals (95% CI) estimated in a Cox regression model stratified by centre, 1-year age and 5-year birth cohort
categories, adjusted for education level (none,/primary school completed, technical/professional school, secondary school, university degree, not
specified), smoking status (never smoker, former smoker who quit <10 years ago, former smoker who quit >10 years ago, former smoker, unknown when
quit, current smoker of 1–14 cigarettes a day, current smoker of 15–24 cigarettes a day, current smoker of > = 25 cigarettes a day, current smoker but
amount missing, smoking status unknown), physical activity (inactive, moderately inactive, moderately active, active), alcohol consumption (0, 0-<5, 5-<15,
15-<30, 30-<60, > = 60 g/day), weight (quintiles), energy intake (kcals/day, continuous). Models in women were further adjusted by menopausal status (pre,
post-, peri-, unknown) and menopausal hormone use (yes, no, unknown).
doi:10.1371/journal.pone.0173117.t006
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by a previous meta-analysis of 1 million people from 121 prospective studies [6]. In the present
study, sitting height was not associated with cancer mortality but was inversely associated with
all-cause mortality, circulatory deaths, and death from respiratory disease. To our knowledge,
this is the first study to report an inverse association between sitting height and death from
respiratory disease. The World Cancer Research Fund/ American Institute for Cancer
Research (WCRF/AICR) reported that there is convincing data that height increases the risk of
individuals being diagnosed with cancers of the colorectum, breast (postmenopausal) and
ovary [20, 21]; furthermore, height ‘probably’ increases the risk of cancers of the pancreas and
breast (premenopausal). To complement this previous data on incidence, our data suggests a
role for height and risk of cancer mortality.
Short stature is a well-documented risk factor for mortality from circulatory diseases [6, 9,
22], ischemic heart disease [23], ischemic stroke [22, 24, 25] and haemorrhagic stroke [24, 25]
in previous studies. The results of this current analysis corroborate these prior studies but we
also observed strong inverse associations between height and subtypes of circulatory disease
death despite their different pathologies.
Whether a relationship between sitting height and mortality also exists is largely unknown.
Wang et al. reported height and sitting height were positively associated with cancer death, but
were inversely associated with death from cardiovascular disease in a cohort of 135,000 Chi-
nese men and women [9]. Four other studies reported no association between sitting height
and mortality [7, 10–12]. Our study in a large European population generally supports the
reports from the Chinese, although we did not find a positive association between sitting
height specifically and cancer mortality.
There are several potential underlying mechanisms to explain the opposing association of
adult height with circulatory disease and cancer mortality. The positive association between
adult height and mortality from cancer may be a result of taller people having larger organs,
and a greater number of cells at risk of malignant transformation and/or proliferation [26].
Furthermore, attained adult height is known to be related to early nutrition in childhood or
adolescence [3, 5]. In contrast, the inverse association between height and cardiovascular dis-
ease mortality has been proposed to be due to taller people and people with higher sitting
height having larger coronary vessel diameters and a slower heart rate and/or greater lung
capacity [8, 27–30]. Height may also be a marker of early exposure to components of the insu-
lin/growth hormone axis. Height is correlated with circulating levels of insulin-like growth fac-
tor (IGF)-I, the main mediator of growth hormone activity and a hormone that has been
positively associated with cancers at a number of anatomic sites [31–35], but IGF-1 levels are
generally inversely related with circulatory disease risk [36–40]. Crowe et al. reported that each
10cm increase in height corresponded to a 4% increase in circulating IGF-1 levels [41]; there-
fore, increasing IGF-1 levels might mediate the opposing effect of height on cancer and circu-
latory disease mortality. To clarify the underlying mechanisms, further studies are needed to
investigate IGF-1 levels in relation to cause-specific mortality risk while accounting for adult
height. Furthermore, several genetic factors are related with height, cancer and cardiovascular
disease [42, 43]. Identifying such genetic variants might shed light on potential mechanisms
underlying the associations between height and mortality.
Davey Smith et al. reported that sitting height was strongly positively associated with insulin
resistance [7]; thus, we expected a clearer association between sitting height and cancer mortal-
ity than overall height. Despite finding a positive association between overall height and cancer
mortality in our data, there was no association for sitting height. These null findings for sitting
height and cancer mortality may be plausible because despite the association with insulin resis-
tance, sitting height has been associated with improved prognosis in cancer survivors due to
better lung function in those with greater sitting height [8, 44]. Our finding that sitting height
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was inversely associated with death from respiratory disease is of note as this may be due to the
aforementioned association between sitting height and lung function [8, 44].
Height is positively associated with education level among women in this study. Previous
studies reported that lower educational levels have been associated with increased mortality,
and incidence of coronary heart disease and stroke in Europe and the United States [45–47].
In an attempt to control for this potential confounder, we adjusted our models for educational
level, although our results did not change from the unadjusted models.
A major strength of the EPIC study is the large study population representing findings
from multiple countries and its long follow-up, resulting in a large number of deaths allowing
us to analyse and distinguish between different causes of death. This study enabled us to exam-
ine measured height on the majority of participants, to adjust the self-reported height variable
in the others, and to examine measured sitting height in a large subset of the cohort. In con-
trast, this study had some limitations. With a large body of information on lifestyle variables,
we could adjust for many potential confounding factors, although the possibility of residual
confounding cannot be excluded. Additionally, we divided cardiovascular disease into sub-
groups, which may result in some degree of misclassification.
In conclusion, this study revealed opposing findings for the relationship between height on
cancer and circulatory disease mortality. Specifically, we showed that height was positively
associated with death from cancer, but inversely associated with death from circulatory dis-
ease. Furthermore, this is the first study to show the inverse association between sitting height
and death from respiratory disease. These findings could be used to contribute to risk predic-
tion models to target individuals for specific screening programmes.
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